Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3379 - Effect of silibinin nutraceutical supplementation in brain metastases of patients with advanced lung cancer

Date

10 Sep 2017

Session

Poster display session

Topics

Central Nervous System Malignancies;  Non-Small Cell Lung Cancer

Presenters

Joaquim Bosch-Barrera

Citation

Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366

Authors

J. Bosch-Barrera1, E. Sais1, A. Izquierdo2, A. Hernández1, D. Roa1, E. Cuyas3, S. Pedraza4, N. Priego5, P. Ortuño4, G. Sánchez4, N. Cañete4, A. Roselló6, R. Soffietti7, J. Brunet1, M. Valiente5, J.A. Menendez3

Author affiliations

  • 1 Medical Oncology Department, Catalan Institute of Oncology, 17007 - Girona/ES
  • 2 Medical Oncology Department, Catalan Institute of Oncology, Girona/ES
  • 3 Metabolism And Cancer Group, Girona Biomedical Research Institute, 17007 - Girona/ES
  • 4 Department Of Radiology, Diagnostic Imaging Institute, Doctor Josep Trueta University Hospital, 17007 - Girona/ES
  • 5 Brain Metastasis Group, CNIO, Madrid/ES
  • 6 Radiotherapy Department, Catalan Institute of Oncology, 17007 - Girona/ES
  • 7 Department Of Neuro-oncology, University of Turin and City of Health and Science Hospital, Torino/IT
More

Resources

Abstract 3379

Background

Silibinin is a bioactive flavonolignan extracted from milk thistle (Silybum marianum). We are currently evaluating the pre-clinical activity of silibinin on reactive astrocytes, a major component of the brain metastasis microenvironment shown to play important pro-metastatic functions.

Methods

We present data of patients with lung cancer and brain metastases that have received compassionate use of nutraceutical supplementation with Legasil®, a commercially available silibinin-based nutraceutical, in addition to standard oncologic treatment. We have compared our observed results with the brain GPA index of each patient calculated by Lung-molGPA tool (brain GPA Index).

Results

Eighteen patients have been treated: median age 62 y (range: 35–80); male: 11 (61%); median number of brain metastases: 4 (range: 1-20); median size of the bigger brain metastasis: 26 mm (range: 10-65 mm). Histology: Adenocarcinoma: 14, Large cell: 1, Small cell: 2, Squamous: 1. All patients have received whole brain radiotherapy. Observed overall survival (OS) was significantly superior compared with expected OS calculated by Lung-molGPA (median 22.2 months [95% CI 13.0-32.6] vs 6.9 months [4.2-9.5]; p = 0.001). Time to central nervous system treatment failure of silibinin was 26.9 months (95% CI 11.7-42.1 months). Brain tumor progression was observed in 6 patients (33%). Overall response rate at brain disease was 75% (Complete Response:3 patients (20%) and Partial Response: 10 patients (55%)). Only one patient presented brain tumor progression as best response. At data cutoff (May 1st, 2017), 6 (33%) patients remained alive.

Conclusions

These preliminary data suggest that silibinin supplementation contributes to the control of brain metastases in lung cancer patients. Further evaluation of the silibinin use in a phase II clinical trial is warranted.

Clinical trial identification

Legal entity responsible for the study

Joaquim Bosch-Barrera

Funding

None

Disclosure

J. Bosch-Barrera: Research grant of SEOM (Sociedad Española de Oncología Médica, Spain) and an Unrestricted Educational Research grant from Meda Pharma (Germany).

\r\n

All other authors have declared no conflicts of interest.

Disclosure

J. Bosch-Barrera: Research grant of SEOM (Sociedad Española de Oncología Médica, Spain) and an Unrestricted Educational Research grant from Meda Pharma (Germany).

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.